PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsNiacin
Wampocap, Tredaptive(niacin)
Niacin, Niacor (niacin) is a small molecule pharmaceutical. Niacin was first approved as Wampocap on 1982-01-01. It is used to treat hypercholesterolemia, hypertriglyceridemia, pellagra, and peripheral vascular diseases in the USA. It is known to target hydroxycarboxylic acid receptor 1, hydroxycarboxylic acid receptor 2, and hydroxycarboxylic acid receptor 3.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
nutritional and metabolic diseasesD009750
Trade Name
FDA
EMA
Niacin, Niacor (discontinued: Niacin, Niaspan titration starter pack, Nicolar, Wampocap)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Niacin
Tradename
Company
Number
Date
Products
NIASPANAbbVieN-020381 DISCN1997-07-28
4 products, RLD
NIASPAN TITRATION STARTER PACKAbbVieN-020381 DISCN1997-07-28
1 products
WAMPOCAPMedpointe Pharm HlcN-011073 DISCN1982-01-01
1 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
011010 niacinamide 4% / tretinoin 0.025%unapproved drug other2020-07-02
011013 niacinamide 4% / tretinoin 0.025%unapproved drug other2020-07-02
011020 niacinamide 4% / tretinoin 0.05%unapproved drug other2020-07-02
011021 niacinamide 4% / tretinoin 0.05%unapproved drug other2020-07-02
011054 niacinamide 4% / spironolactone 5%unapproved drug other2020-07-02
011218 niacinamide 2% / spironolactone 5% / tretinoin 0.025%unapproved drug other2020-07-02
011220 niacinamide 2% / spironolactone 5% / tretinoin 0.05%unapproved drug other2020-07-02
011312 niacinamide 4% / tazarotene 0.05%unapproved drug other2020-07-02
011503 dapsone 6% / niacinamide 2% / spironolactone 5%unapproved drug other2020-07-02
011504 dapsone 8.5% / niacinamide 4%unapproved drug other2020-07-02
Show 735 more
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hypercholesterolemia—D006937—
hypertriglyceridemiaEFO_0004211D015228—
peripheral vascular diseasesEFO_0003875D016491I73.9
pellagra—D010383—
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C04: Peripheral vasodilators
— C04A: Peripheral vasodilators
— C04AC: Nicotinic acid and derivatives, peripheral vasodilators
— C04AC01: Nicotinic acid
— C10: Lipid modifying agents
— C10A: Lipid modifying agents, plain
— C10AD: Nicotinic acid and derivatives, lipid modifying, plain
— C10AD02: Nicotinic acid
— C10AD52: Nicotinic acid, combinations
— C10B: Lipid modifying agents, combinations
— C10BA: Combinations of various lipid modifying agents
— C10BA01: Lovastatin and nicotinic acid
HCPCS
No data
Clinical
Clinical Trials
1471 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
CarcinomaD002277—C80.07314762942294
Hepatocellular carcinomaD006528—C22.066111591036243
Liver neoplasmsD008113EFO_1001513C22.071110461032231
Renal cell carcinomaD002292EFO_0000376—17441612092
NeoplasmsD009369—C80582671690
DyslipidemiasD050171——651314745
Healthy volunteers/patients———254—11444
HypercholesterolemiaD006937——42173632
Cardiovascular diseasesD002318EFO_0000319I98321011025
Type 2 diabetes mellitusD003924EFO_0001360E117663525
Show 89 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
RecurrenceD012008——12312—243
LeukemiaD007938—C9518245—542
Myeloid leukemia acuteD015470—C92.021193—440
Lung neoplasmsD008175—C34.9011244——36
Myeloid leukemiaD007951—C9213192—432
Non-small-cell lung carcinomaD002289——11195—132
Breast neoplasmsD001943EFO_0003869C509231—230
MelanomaD008545——10172——27
Thyroid diseasesD013959—E00-E07—183—322
Kidney neoplasmsD007680EFO_0003865C64783—320
Show 129 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SarcomaD012509——711———16
Prostatic neoplasmsD011471—C61610——115
Colorectal neoplasmsD015179——510——215
GlioblastomaD005909EFO_0000515—710——114
InflammationD007249MP_0001845—23——1014
Myelodysplastic syndromesD009190—D4679———13
Precursor cell lymphoblastic leukemia-lymphomaD054198—C91.075———11
Brain neoplasmsD001932EFO_0003833C7185——111
Heart failureD006333EFO_0003144I5035——310
Chronic obstructive pulmonary diseaseD029424EFO_0000341J44.935——210
Show 229 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Metabolic diseasesD008659EFO_0000589E88.94———59
Hematologic neoplasmsD019337——3———14
PharmacokineticsD010599——3———14
Abdominal obesityD056128——1———23
Glucose intoleranceD018149HP_0000833R73.031———23
Prediabetic stateD011236EFO_1001121R73.031———23
Mitochondrial diseasesD028361EFO_0000591—1———23
Megakaryoblastic leukemia acuteD007947—C94.23————3
Myelomonocytic leukemia acuteD015479—C92.53————3
Basophilic leukemia acuteD015471—C94.83————3
Show 69 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Iron deficienciesD000090463—E61.1————55
DermatitisD003872—L30.9————44
Healthy agingD000073656——————44
Diet therapyD004035——————33
ConstipationD003248—K59.0————33
Congenital heart defectsD006330—Q24.9————33
Respiratory tract infectionsD012141—J06.9————33
CognitionD003071EFO_0003925—————33
ExerciseD015444EFO_0000483—————33
Heart valve diseasesD006349EFO_0009551I08————33
Show 132 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameNiacin
INNnicotinic acid
Description
Nicotinic acid is a pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group. It has a role as an antidote, an antilipemic drug, a vasodilator agent, a metabolite, an EC 3.5.1.19 (nicotinamidase) inhibitor, an Escherichia coli metabolite, a mouse metabolite, a human urinary metabolite and a plant metabolite. It is a vitamin B3, a pyridinemonocarboxylic acid and a pyridine alkaloid. It is a conjugate acid of a nicotinate.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
O=C(O)c1cccnc1
Identifiers
PDB—
CAS-ID59-67-6
RxCUI—
ChEMBL IDCHEMBL573
ChEBI ID15940
PubChem CID938
DrugBankDB00627
UNII ID2679MF687A (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
CA2
CA2
Organism
Homo sapiens
Gene name
CA2
Gene synonyms
NCBI Gene ID
760
Protein name
carbonic anhydrase 2
Protein synonyms
CA-II, CAC, Carbonate dehydratase II, carbonic anhydrase B, Carbonic anhydrase C, Carbonic anhydrase II, carbonic dehydratase, Cyanamide hydratase CA2, epididymis luminal protein 76, epididymis secretory protein Li 282
Uniprot ID
Q96ET9
Mouse ortholog
Car2 (12349)
carbonic anhydrase 2 (Q9DCY9)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Niaspan – AbbVie
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Niacin
+
Lovastatin
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Niacin
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Niacin
+
Simvastatin
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 22,426 documents
View more details
Safety
Black-box Warning
Black-box warning for: Citranatal 90 dha, Citranatal assure, Citranatal dha, Citranatal essence, Citranatal rx, Healthy mamabe well rounded, Marnatal f, Moms choice rx, Natafort, Nestabs, Nestabs dha, O-cal prenatal vitamin, Pnv prenatal plus multivitamin, Pnv prenatal vitamin, Pnv-select, Pr natal 400, Pr natal 400 ec, Pr natal 430, Pr natal 430 ec, Pre-tabs dha, Prenata, Prenatal plus multivitamin plus dha minicaps, Prenate elite, Select ob, Select-ob plus dha, Tristart dha, Vitafol, Vitafol fe plus, Vitafol ob, Vitafol-ob plus dha
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
48,671 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use